Biologics Market Projected to Double by 2035, Driven by Oncology and Engineered Antibodies

  • The global biologics market is projected to grow from USD 406.09 billion in 2025 to USD 755.83 billion by 2035, a CAGR of 6.41%.
  • North America held the largest regional share at 48.0% in 2025, while Asia Pacific is expected to record the fastest growth at 7.73% annually.
  • Monoclonal antibodies represented 55.0% of product revenue in 2025, with bispecific antibodies being the fastest-growing product category at a modeled 15.13% CAGR.
  • Oncology accounted for 36.0% of indication spending in 2025, with rare and genetic disorders representing a faster-growing treatment niche.
  • Parenteral products represented 95.0% of sales, highlighting the critical role of injection and infusion infrastructure.

The biologics market is poised for significant growth, driven by the increasing use of monoclonal antibodies in oncology and chronic disease treatment. The next competitive phase will be shaped by the introduction of next-generation therapies, such as bispecific antibodies and advanced cell therapies, alongside the growing influence of biosimilars. Companies that can demonstrate clinical benefit, ensure reliable manufacturing, and navigate payer decisions will sustain pricing power and market share.

Product Innovation
How the introduction of bispecific antibodies and advanced cell therapies will impact market dynamics and competitive positioning.
Regulatory Shifts
Whether the FDA's draft guidance on biosimilar development will accelerate market entry and price competition.
Regional Expansion
The pace at which Asia Pacific can sustain its growth rate, driven by increasing biologics production and broader insurance coverage.